Studien

CONKO-11 Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients AIO-SUP-0115/ass. · Studie beendet Studie anzeigen

ALPACA First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine (ALPACA) AIO-PAK-0114 · Rekrutierung beendet Studie anzeigen

NIVOSWITCH A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor AIO-NZK-0116ass · Rekrutierung beendet Studie anzeigen

GrantPax A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients AIO-GER-0115 · Rekrutierung beendet Studie anzeigen

CaBaMet A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) AIO-ZNS-0113 · Studie beendet Studie anzeigen

CRISP Clinical Researchplatform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP)
Hauptprojekt (NSCLC Stadium IV, IIIB/C palliative AIO-TRK-0315 · In Rekrutierung Studie anzeigen

NeoIntercal Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal) AIO-TRK-0214 · Studie beendet Studie anzeigen

MARBLE Maintaining ERBB Blockade in EGFR-mutated Lung Cancer (MARBLE) AIO-TRK-0114 · Rekrutierung beendet Studie anzeigen

NEONAX Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer: - A prospective, randomized, controlled, phase II study of the AIO Pancreatic Cancer Group (NEONAX) AIO-PAK-0313 · Rekrutierung beendet Studie anzeigen

Evinec Safety and Tolerability of Everolimus as second–line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3 AIO-NET-0112 · Studie beendet Studie anzeigen